glp-1 and ulcerative colitis Frontiers The Potential for GLP-1s in
Description
The use of GLP-1 RAs for treating OSA offers a promising alternative or adjunct to CPAP, particularly in patients with obesity or metabolic dysfunction
Market Trends and Insights Drivers Impact Analysis of Anti-obesity Drugs Market * Escalating Cardiometabolic Complications Driving Early Pharmacologic Intervention Cardiologists and primary-care physicians now regard obesity as a cardiovascular risk factor comparable to smoking, following the American Heart Associations 2024 statement that reclassified the condition [1]American Heart Association, 2024 Scientific Statement on Obesity, heart.org
[DOI] [PubMed] [Google Scholar] 98.Younossi Z.M., Kalligeros M., Henry L
GLP-1 drugs like Ozempic and Wegovy have gained attention for their effectiveness in weight loss
